Please select the option that best describes you:
In the high-risk adjuvant or metastatic setting when you initiate patients on ovarian suppression with the plan to start an AI, what protocol do you follow in terms of rechecking estradiol?
How often will you monitor it? In the setting that patient is morbidly obese, does your strategy change?
Answer from: Medical Oncologist at Academic Institution
This is an area of intense interest, as well as uncertainty. In truth, unless the patient does not have a uterus, (unusual in premenopause) I typically follow clinical menses and have not followed estradiol.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree that there are little available data to guide us in this setting. I generally check ultrasensitive estradiol monthly (immediately prior to the GnRHa injection) before starting the AI and then for a few months on the AI therapy. If in the postmenopausal range I will start the AI therapy, and ...